Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
about
Clinical applications of Gallium-68Imaging of gastroenteropancreatic neuroendocrine tumorsSimple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapyDetection of neuroendocrine tumours in the small intestines using contrast-enhanced multiphase Ga-68 DOTATOC PET/CT: the potential role of arterial hyperperfusion(68)Ga-labeled radiopharmaceuticals for positron emission tomography.68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET.Ga-68 DOTATATE positron emission tomography/computer tomography in initial staging and therapy response evaluation in a rare case of primary neuroblastoma in neckItalian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms.Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CTMultimodal management of neuroendocrine liver metastases.Effect of Peptide Receptor Radionuclide Therapy on Somatostatin Receptor Status and Glucose Metabolism in Neuroendocrine Tumors: Intraindividual Comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/CT.Receptor-mediated tumor targeting with radiopeptides. Part 1. General concepts and methods: applications to somatostatin receptor-expressing tumors.Updated and new perspectives on diagnosis, prognosis, and therapy of malignant pheochromocytoma/paraganglioma.Pheochromocytoma: physiopathologic implications and diagnostic evaluation.Ga-68 DOTANOC PET/CT imaging in detection of primary site in patients with metastatic neuroendocrine tumours of unknown origin and its impact on clinical decision making: experience from a tertiary care centre in IndiaDoes PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrRadiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency.Repeatability of gallium-68 DOTATOC positron emission tomographic imaging in neuroendocrine tumors.PET/CT imaging of neuroendocrine tumors with (68)Gallium-labeled somatostatin analogues: An overview and single institutional experience from India.Efficient bifunctional gallium-68 chelators for positron emission tomography: tris(hydroxypyridinone) ligands⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.The value of preoperative imaging in small bowel neuroendocrine tumors.Preclinical imaging: an essential ally in modern biosciences.Neuroendocrine tumours: the role of imaging for diagnosis and therapy.68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETsStatus and trends in the development of clinical diagnostic agents.68Ga-DOTA and analogs: Current status and future perspectivesMolecular Imaging Radiotherapy: Theranostics for Personalized Patient Management of Neuroendocrine Tumors (NETs).Impact of bifunctional chelators on biological properties of 111In-labeled cyclic peptide RGD dimers.Exploring new frontiers in molecular imaging: Emergence of Ga PET/CT.An orthotopic model of pancreatic somatostatin receptor (SSTR)-positive tumors allows bimodal imaging studies using 3T MRI and animal PET-based molecular imaging of SSTR expression.Evaluation of (68)Ga-DOTA-TOC PET/CT for the detection of duodenopancreatic neuroendocrine tumors in patients with MEN1.Nuclear medicine imaging and therapy of neuroendocrine tumours.THERANOSTICS: From Molecular Imaging Using Ga-68 Labeled Tracers and PET/CT to Personalized Radionuclide Therapy - The Bad Berka Experience.Somatostatin receptor-based molecular imaging and therapy for neuroendocrine tumors.Clinically silent chromaffin-cell tumors: Tumor characteristics and long-term prognosis in patients with incidentally discovered pheochromocytomas.Physiological and tumoral uptake of (68)Ga-DOTATATE: standardized uptake values and challenges in interpretation.Twins in spirit part II: DOTATATE and high-affinity DOTATATE--the clinical experience.Is ⁶⁸Ga-DOTA-NOC PET/CT indicated in patients with clinical, biochemical or radiological suspicion of neuroendocrine tumour?Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA.
P2860
Q26849276-582F47DB-1D71-4DED-8229-3710FF2BAFD8Q28238305-B5E1AFB9-5EDC-4812-A60B-3D4C742908C7Q28397980-94B39723-81B1-44E5-99C0-B4972FBA4749Q30435499-C5CFAD6C-9E61-40E4-96E6-B08DED8F09FFQ33704038-ACC26893-22BF-46CD-BFAE-2D8625063C8BQ33915233-0181E77A-6FBD-46DD-8AE6-4B4A875A09D2Q34147065-34B5B23D-76B4-45AA-872A-328FDBCDCFE1Q34157385-AAAEF7DB-2914-4286-9FD3-A41C6D1EB68AQ34503869-24F555FE-01D4-427A-8754-D045EFA97389Q34528199-39D4DA1B-E7C4-41A6-8581-F659A740278BQ35550939-8891F760-9CD2-463C-B4B1-5BAF50B76979Q36008285-04D7BAB4-F191-4068-96DF-54614857F04BQ36125143-7AF48D72-A847-4718-B4E8-A8C7D287373DQ36694028-E2E5D6D9-C0D9-47FC-B7DA-AE6AB305866AQ36936960-7D420218-1A42-4030-BAF8-9DAF34EA9520Q37425156-F18562E3-BD1F-437B-B052-02D823CCAEB4Q37480688-22C52ECA-0832-4822-80F6-201B92765915Q37504159-E123334C-C08E-4C0D-BF57-18BA632A8AA6Q37592451-B196F587-CB9A-4E13-80AA-40BC09800103Q37594420-C30ABBE6-46E8-4F6C-9995-0D47AECA4BA7Q37990397-A8128A9D-F6F3-47C1-A68B-AE48337BC89DQ38071233-F49E3B21-FCB0-4FC3-877E-BC14E84FEC81Q38154514-0DF2D16A-F4DA-4E26-A810-4838B937794FQ38169928-F9879A22-A5A8-40D0-9374-777A76CE4BB5Q38241463-C2331383-3B03-4170-9BDC-A48C10CB931AQ38995734-F078A877-414F-4D7A-83D9-39361A852FA0Q39191325-195CBD83-20EC-4C43-9926-AE3E6927BCACQ39590717-02D98506-7CB6-4E68-A4D6-7D1AD6A4EC78Q39755513-C9CA23D5-6859-4DDB-A431-8B99B759B226Q39805119-827D701E-6B91-422F-BD0C-33D993542D4FQ39822404-E3715D4D-B390-4A4B-B30E-0C2065E8A70AQ40051095-5C63DDC5-DF1E-4278-B08E-2047BE3210E8Q40268569-B3F1472F-444A-4711-A48E-47C240C474EBQ42068740-FE35E34E-B759-418D-90AE-EC3BAB9E3BA5Q42548064-71DB37DD-CAA4-4AB6-AF6D-86D3E2841E10Q43061012-AB5F9056-603E-4496-8F48-951094272766Q43774881-B268598A-AF8E-41E2-9C5F-F370D5A981B1Q44556742-AEE04FFA-EFE1-445A-B67F-08E93DB616B6Q46152235-A24CEF17-7E11-4C67-A26B-07D9154477A6Q48089118-9A52D062-ACD7-46AC-8843-DBABB94FB3C5
P2860
Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe
@nl
Evaluation of positron emissio ...... ts with neuroendocrine tumors.
@ast
Evaluation of positron emissio ...... ts with neuroendocrine tumors.
@en
type
label
Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe
@nl
Evaluation of positron emissio ...... ts with neuroendocrine tumors.
@ast
Evaluation of positron emissio ...... ts with neuroendocrine tumors.
@en
prefLabel
Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe
@nl
Evaluation of positron emissio ...... ts with neuroendocrine tumors.
@ast
Evaluation of positron emissio ...... ts with neuroendocrine tumors.
@en
P2093
P1476
Evaluation of positron emissio ...... ts with neuroendocrine tumors.
@en
P2093
Helmut R Mäcke
Jochen Schuhmacher
Jörg Kowalski
Marcus Henze
Michael Hofmann
Uwe Haberkorn
P356
10.1016/S1536-1632(03)00038-6
P577
2003-01-01T00:00:00Z